What are the details of your prescription?
Bumex
Generic Name: Bumetanide
Drug Category: Loop Diuretic
Litigation Alert Level: Low
This drug has been approved for use by males and females over the age of 18 years old for a maximum duration of 1 year.
| Approved Uses |
|
Indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Bumetanide is contraindicated in anuria. Bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition is improved or corrected. In patients with hepatic cirrhosis and ascites, sudden alterations of electrolyte balance may precipitate hepatic encephalopathy and coma. Treatment in such patients is best initiated in the hospital with small doses and careful monitoring of the patient’s clinical status and electrolyte balance. Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. Patients under treatment should be observed regularly for possible occurrence of blood dyscrasias, liver damage or idiosyncratic reactions, which have been reported occasionally in foreign marketing experience. Hypokalemia can occur as a consequence of Bumex administration. Serious skin reactions (i.e., Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported in association with bumetanide use. Potentiation of aminoglycoside ototoxicity has not been tested for bumetanide. Like other members of this class of diuretics, bumetanide probably shares this risk. Since there have been rare spontaneous reports of thrombocytopenia from postmarketing experience, patients should be observed regularly for possible occurrence of thrombocytopenia. Hyperuricemia may occur; it has been asymptomatic in cases reported to date. Reversible elevations of the BUN and creatinine may also occur, especially in association with dehydration and particularly in patients with renal insufficiency. Bumex may increase urinary calcium excretion with resultant hypocalcemia. Diuretics have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia. Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. Lithium should generally not be given with diuretics. Probenecid should not be administered concurrently with Bumex. Concurrent therapy with Indomethacin is not not recommended. Bumex may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. There are no adequate and well-controlled studies in pregnant women. Animal studies: moderate growth retardation and increased incidence of delayed ossification of sternebrae As a general rule, nursing should not be undertaken while the patient is on bumetanide since it may be excreted in human milk. |
| Off-label Uses |
|
• Use in patients under the age of 18. GoToSource • Autism. GoToSource • Idiopathic intracranial hypertension. GoToSource • Hypercalcemia. GoToSource • Epilepsy and ischemic and traumatic brain injury. GoToSource • Neonatal seizures. GoToSource • Schizophrenia. GoToSource • Adjunctive therapy for temporal lobe epilepsy. GoToSource • Oliguric acute renal failure in preterm infants. GoToSource • Adjunctive treatment for diabetes. GoToSource • Reduce severity of autism spectrum disorders. GoToSource • Fragile x syndrome. GoToSource • Nocturia. GoToSource |
| Adverse Events |
|
Decreased bone mineral density. GoToSource Pancreatitis (inflammation of the pancreas). GoToSource Increased risk of fracture. GoToSource Development of dyslipidemia (abnormal amount of lipids in the blood) after heart transplantation. GoToSource Phototoxicity. GoToSource Hypokalemia (low blood potassium level), interstitial nephritis (kidney disorder) and thrombocytopenia (low blood platelet count). GoToSource Hypochloremia (low blood levels of chloride), alkalosis and hyperuricemia (high level of uric acid in the blood). GoToSource Hearing loss. GoToSource Prerenal azotemia (abnormally high level of nitrogen waste products in the blood) and myalgias (muscle pain). GoToSource |
| Litigation |
|
No major injury lawsuits reported. |
The material contained in GoToPills is for informational purposes only and not intended to replace the judgment, evaluation and treatment of physicians, pharmacists and other healthcare providers. GoToPills does not provide medical advice, diagnoses or treatment. Always seek the advice of your physician or other qualified health provider regarding a medical condition or treatment.
